AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 65(6), 2001, pp. 685-689
Copyright © 2001 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietze, R
Right arrow Articles by Grogl, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietze, R
Right arrow Articles by Grogl, M
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Leishmaniasis
Related Collections
Right arrow Travel Medicine
Right arrow Leishmaniasis
American Journal of Tropical Medicine and Hygiene, Vol 65, Issue 6, 685-689
Copyright © 2001 by American Society of Tropical Medicine and Hygiene

Research Articles


Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi

R Dietze, SF Carvalho, LC Valli, J Berman, T Brewer, W Milhous, J Sanchez, B Schuster, and M Grogl

There are no recognized orally administered treatments for any of the leishmaniases. The 8-aminoquinoline WR6026 is an orally administered analog of primaquine that cured 50% of patients with kala-azar in Kenya at a dose of 1 mg/kg/day for 28 days. A further phase 2, open-label, dose-escalating safety and efficacy study was performed for kala-azar in Brazil. Cure rates for Brazilian patients treated for 28 days were as follows: 1 mg/kg/day: 0 of 4 (0%); 1.5 mg/kg/day: 1 of 6 (17%); 2.0 mg/kg/day: 4 of 6 (67%); 2.5 mg/kg/day: 1 of 5 (20%); and 3.25 mg/kg/day: 0 of 1 (0%). Nephrotoxicity that was not anticipated from preclinical animal studies or from phase 1 studies was seen at 2.5 mg/kg/day in 2 patients and in the single patient administered 3.25 mg/kg/day. WR6026 demonstrated the unusual clinical features of lack of increased efficacy against Brazilian kala-azar with increased dosing above 2 mg/kg/day and toxicity that was not present in previous investigations.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. P. D. Nanayakkara, A. L. Ager Jr., M. S. Bartlett, V. Yardley, S. L. Croft, I. A. Khan, J. D. McChesney, and L. A. Walker
Antiparasitic Activities and Toxicities of Individual Enantiomers of the 8-Aminoquinoline 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-Dichlorophenoxy]Quinoline Succinate
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2130 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
T. V Piscopo and C. Mallia Azzopardi
Leishmaniasis.
Postgrad. Med. J., February 1, 2007; 83(976): 649 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
T V Piscopo and A C Mallia
Leishmaniasis.
Postgrad. Med. J., October 1, 2006; 82(972): 649 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
S. L. Croft, S. Sundar, and A. H. Fairlamb
Drug Resistance in Leishmaniasis
Clin. Microbiol. Rev., January 1, 2006; 19(1): 111 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
T. K. JHA, S. SUNDAR, C. P. THAKUR, J. M. FELTON, A. J. SABIN, and J. HORTON
A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA
Am J Trop Med Hyg, December 1, 2005; 73(6): 1005 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
M. K. WASUNNA, J. R. RASHID, J. MBUI, G. KIRIGI, D. KINOTI, H. LODENYO, J. M. FELTON, A. J. SABIN, and J. HORTON
A PHASE II DOSE-INCREASING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN KENYA
Am J Trop Med Hyg, November 1, 2005; 73(5): 871 - 876.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. G. Tempone, A. C. M. Pompeu da Silva, C. A. Brandt, F. S. Martinez, S. E. Treiger Borborema, M. A. Barata da Silveira, and H. F. de Andrade Jr.
Synthesis and Antileishmanial Activities of Novel 3-Substituted Quinolines
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1076 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Demicheli, R. Ochoa, J. B. B. da Silva, C. A. B. Falcao, B. Rossi-Bergmann, A. L. de Melo, R. D. Sinisterra, and F. Frezard
Oral Delivery of Meglumine Antimoniate-{beta}-Cyclodextrin Complex for Treatment of Leishmaniasis
Antimicrob. Agents Chemother., January 1, 2004; 48(1): 100 - 103.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Tropical Medicine and Hygiene.